{"meta":{"query_hash":"ebacd331f739","filters":{"venue":"touchREVIEWS in Oncology & Haematology"},"cohort_total":12,"direct_labels_cover":0,"predictions_cover":12,"exported":12,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/ebacd331f739","api":"https://metacan.xera.ac/api/v1/cohort?venue=touchREVIEWS+in+Oncology+%26+Haematology"},"results":[{"id":"W2493321731","doi":"10.17925/ohr.2012.08.2.123","title":"Trauma-related Coagulopathy—Current Concepts","year":2012,"lang":"en","type":"article","venue":"touchREVIEWS in Oncology & Haematology","topic":"Trauma, Hemostasis, Coagulopathy, Resuscitation","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Coagulopathy; Medicine; Intensive care medicine; Consumptive Coagulopathy; Surgery","score_opus":0.059250287827643286,"score_gpt":0.42475013974147724,"score_spread":0.36549985191383394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2493321731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.844399,0.12583269,0.00030868643,0.003601036,0.004464109,0.0027022958,0.0000133974845,0.00026503578,0.018413763],"genre_scores_gemma":[0.98799163,0.0067169503,0.0025871575,0.001527891,0.00029797773,0.00049191667,0.0001301127,0.000074219024,0.00018215491],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946123,0.0011824162,0.0018900099,0.0006797605,0.00033881425,0.0012967099],"domain_scores_gemma":[0.99723494,0.00072678825,0.0005937938,0.00077235047,0.00018477811,0.00048737583],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0018841696,0.00052330224,0.002460254,0.00048510087,0.00010812,0.000009078545,0.0003129985,0.0007080859,0.0010391866],"category_scores_gemma":[0.0010968957,0.00046626868,0.00031747966,0.00080963783,0.0006118634,0.00026073345,0.00012802467,0.0011519577,0.0019063035],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029039264,0.0018771159,0.11867403,0.0008596079,0.00009575565,0.00060405117,0.003745653,0.0000030684657,0.00053560955,0.008777356,0.007008675,0.8575287],"study_design_scores_gemma":[0.008664179,0.0010983242,0.14890112,0.0010401767,0.0005860591,0.008399959,0.00078710326,0.000088168126,0.0015729938,0.001046032,0.8270017,0.00081420894],"about_ca_topic_score_codex":0.000023500652,"about_ca_topic_score_gemma":0.00013468364,"teacher_disagreement_score":0.8567145,"about_ca_system_score_codex":0.00068679184,"about_ca_system_score_gemma":0.0004014317,"threshold_uncertainty_score":0.999874},"labels":[],"label_agreement":null},{"id":"W2495051483","doi":"10.17925/ohr.2014.10.2.110","title":"Systemic Treatment for Gastrointestinal Stromal Tumor—A State of Art","year":2014,"lang":"en","type":"article","venue":"touchREVIEWS in Oncology & Haematology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services","funders":"","keywords":"GiST; Regorafenib; Sunitinib; Medicine; Imatinib; Stromal tumor; Tyrosine-kinase inhibitor; Imatinib mesylate; Oncology; Targeted therapy; Tyrosine kinase; Internal medicine; Adjuvant; Cancer research; Stromal cell; Cancer; Receptor; Colorectal cancer","score_opus":0.04687913405771255,"score_gpt":0.3725796975989255,"score_spread":0.32570056354121296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2495051483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837147,0.002120717,0.00530509,0.0016882147,0.00013671828,0.0037519173,0.00003507089,0.00006562763,0.0031819318],"genre_scores_gemma":[0.9606026,0.00027194753,0.03722615,0.00021049358,0.00007384244,0.0010392372,0.00006710585,0.000039676182,0.0004689835],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9970152,0.0004493453,0.00109801,0.00049510284,0.00017238432,0.00076998066],"domain_scores_gemma":[0.9977038,0.00092927204,0.00041064876,0.0004839092,0.0001991302,0.00027326186],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007506474,0.00033609036,0.0021043168,0.0002783676,0.000043107502,0.000004512343,0.00016538217,0.00004940924,0.00009621899],"category_scores_gemma":[0.0009561109,0.00024954937,0.00029588904,0.00018235417,0.0003053763,0.000036301153,0.0000559311,0.00021778239,0.00017113084],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009421931,0.009591758,0.6770313,0.00814532,0.0005201576,0.015069343,0.00041856559,0.00011705719,0.01866792,0.010888326,0.0062133796,0.24391499],"study_design_scores_gemma":[0.053402223,0.18282357,0.044338133,0.011775495,0.001379283,0.5359281,0.00037917474,0.004830125,0.01139083,0.0047305473,0.14792776,0.0010948082],"about_ca_topic_score_codex":0.000049688653,"about_ca_topic_score_gemma":0.00018668671,"teacher_disagreement_score":0.6326931,"about_ca_system_score_codex":0.0005219633,"about_ca_system_score_gemma":0.0005092899,"threshold_uncertainty_score":0.99999565},"labels":[],"label_agreement":null},{"id":"W2498090476","doi":"10.17925/ohr.2015.11.01.19","title":"A Systematic Review of Factors Influencing Older Adults’ Hypothetical Treatment Decisions","year":2015,"lang":"en","type":"review","venue":"touchREVIEWS in Oncology & Haematology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Council of University Libraries; Université de Montréal; Princess Margaret Cancer Centre; McGill University; Children's Hospital of Eastern Ontario; Jewish General Hospital; University Health Network; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Cancer treatment; Willingness to accept; Older people; Systematic review; Cancer; Gerontology; Willingness to pay; Demography; MEDLINE; Internal medicine","score_opus":0.27017614399736867,"score_gpt":0.5190729546122294,"score_spread":0.2488968106148607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2498090476","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020049476,0.9898335,0.000020678255,0.00009627992,0.0003147645,0.008070327,0.00005442987,0.000033878427,0.0013756544],"genre_scores_gemma":[0.000009967849,0.99624896,0.0016803527,0.00031463878,0.000047971313,0.0013790581,0.00016046801,0.0000760565,0.000082516446],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.98995346,0.0024709296,0.0057685,0.00077769527,0.00043685248,0.00059254206],"domain_scores_gemma":[0.989614,0.0051621743,0.0029135866,0.0014613273,0.00052288675,0.0003260315],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0016272301,0.0009616593,0.025595723,0.0006947337,0.00002735875,0.0000027856506,0.0005342186,0.0011130414,0.00024859884],"category_scores_gemma":[0.009358634,0.0005742076,0.0018694403,0.0008942095,0.00045508204,0.000047514066,0.00017432927,0.00063314347,0.00018407172],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020863623,0.0004962296,0.00008399996,0.83307874,0.00057562394,0.00046956993,0.0008377278,2.1871632e-8,5.8204364e-8,0.00019409541,0.00060688186,0.16363616],"study_design_scores_gemma":[0.0006764265,0.0005636599,0.0000014617992,0.58008355,0.0068538664,0.001032498,0.00018056533,4.5442562e-7,0.0000017204853,0.00001850665,0.4103833,0.00020399144],"about_ca_topic_score_codex":0.00007351927,"about_ca_topic_score_gemma":0.00005223809,"teacher_disagreement_score":0.40977642,"about_ca_system_score_codex":0.0012280059,"about_ca_system_score_gemma":0.0022690336,"threshold_uncertainty_score":0.9996709},"labels":[],"label_agreement":null},{"id":"W2504029159","doi":"10.17925/ohr.2010.06.0.42","title":"Pre-operative Targeted Therapies in Patients with Hepatic Colorectal Cancer Metastases—Bevacizumab versus Cetuximab","year":2010,"lang":"en","type":"article","venue":"touchREVIEWS in Oncology & Haematology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Cetuximab; Bevacizumab; Colorectal cancer; Oncology; Chemotherapy; Internal medicine; Disease; Systemic therapy; Cancer; Surgery","score_opus":0.01792331745637213,"score_gpt":0.347404386023866,"score_spread":0.3294810685674938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2504029159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983635,0.009965452,0.000004284188,0.001348163,0.0007269833,0.002534974,0.00004136614,0.00005079235,0.0016929934],"genre_scores_gemma":[0.9934889,0.0023053936,0.0014515172,0.0004643625,0.000052970627,0.002051683,0.000072533614,0.000037535257,0.00007511337],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99734366,0.00039613797,0.00078169437,0.00063269126,0.00022359335,0.0006222164],"domain_scores_gemma":[0.9986171,0.00045519604,0.00027533274,0.00033331616,0.00020117195,0.00011784679],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003103926,0.00044998765,0.0021866793,0.00027588336,0.00010628952,0.000009506815,0.00017505352,0.00027896947,0.0009647167],"category_scores_gemma":[0.00028295655,0.00030019932,0.00012792362,0.000521927,0.0005070869,0.0001186665,0.000102556674,0.0007524612,0.00003605791],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016987795,0.0028218357,0.8996297,0.00023074758,0.00086320494,0.0007386369,0.0044449433,0.000006296471,0.00022005278,0.00052491855,0.00070743315,0.07282444],"study_design_scores_gemma":[0.043956317,0.011816601,0.9037836,0.00033256906,0.0007236646,0.00016854292,0.00047256285,0.00006121602,0.000828808,0.00011473535,0.037125796,0.0006155468],"about_ca_topic_score_codex":0.000762798,"about_ca_topic_score_gemma":0.049294274,"teacher_disagreement_score":0.0722089,"about_ca_system_score_codex":0.0005946679,"about_ca_system_score_gemma":0.0005774748,"threshold_uncertainty_score":0.99994856},"labels":[],"label_agreement":null},{"id":"W2617733729","doi":"10.17925/ohr.2017.13.01.41","title":"Paraneoplastic Syndromes in Children with Hodgkin Lymphoma","year":2017,"lang":"en","type":"article","venue":"touchREVIEWS in Oncology & Haematology","topic":"Autoimmune Neurological Disorders and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Malignancy; Limbic encephalitis; Lymphoma; Hodgkin lymphoma; Pathophysiology; Pathology; Antibody; Immunology; Autoantibody","score_opus":0.03430934729151551,"score_gpt":0.3440599411965141,"score_spread":0.3097505939049986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2617733729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835038,0.0067142574,0.000026738593,0.0025603187,0.00012764697,0.0012578339,0.0000027068884,0.000040282644,0.0057663727],"genre_scores_gemma":[0.9938581,0.0038848533,0.0005504865,0.0011862654,0.00001554835,0.00031288428,0.000019486652,0.00002595779,0.00014641276],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978223,0.0002700578,0.0006379887,0.0005780084,0.00012430073,0.0005673693],"domain_scores_gemma":[0.9984553,0.00021762322,0.000364984,0.0008360758,0.000026353517,0.00009968732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024793806,0.0003225078,0.0018956319,0.00018918392,0.00013785248,0.000013569085,0.00035822447,0.00036105406,0.00025932686],"category_scores_gemma":[0.00044283643,0.00021788222,0.00011097941,0.00013244049,0.00057129294,0.00008399769,0.00014616709,0.00031581824,0.0002884025],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003563274,0.0011477023,0.91292816,0.00006473827,0.00009940149,0.0068816273,0.000056184293,0.0000040734803,0.000007193135,0.00061758084,0.00013531833,0.0777017],"study_design_scores_gemma":[0.008416786,0.0019994637,0.9668247,0.00022310959,0.00014723683,0.015031135,0.000011750308,0.000035028126,0.000014850477,0.0006155556,0.0064921263,0.00018823969],"about_ca_topic_score_codex":0.00026668192,"about_ca_topic_score_gemma":0.0006578805,"teacher_disagreement_score":0.077513464,"about_ca_system_score_codex":0.00012190947,"about_ca_system_score_gemma":0.00020160901,"threshold_uncertainty_score":0.8884979},"labels":[],"label_agreement":null},{"id":"W2619722962","doi":"10.17925/ohr.2017.13.01.19","title":"Raising the Bar in Advanced Pancreatic Cancer","year":2017,"lang":"en","type":"article","venue":"touchREVIEWS in Oncology & Haematology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"FOLFIRINOX; Gemcitabine; Medicine; Oxaliplatin; Irinotecan; Pancreatic cancer; Oncology; Internal medicine; Randomized controlled trial; Clinical trial; First line; Cancer; Colorectal cancer","score_opus":0.11714557525357153,"score_gpt":0.47556778613374595,"score_spread":0.35842221088017445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2619722962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90639824,0.022859672,0.000066408844,0.030597286,0.00045710977,0.0019241046,0.0000027453816,0.000027355783,0.03766711],"genre_scores_gemma":[0.9625898,0.03034054,0.0015386728,0.0028590346,0.00014952788,0.0012685186,0.000005856697,0.000032392825,0.0012156749],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99658704,0.00081617123,0.0010085072,0.0005385213,0.00020639705,0.0008433778],"domain_scores_gemma":[0.99675214,0.0012179641,0.0004521031,0.001328978,0.00009894465,0.00014989045],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020856396,0.00028426526,0.0024683014,0.00021696601,0.00033660815,0.000019054587,0.0006934335,0.00043353363,0.0010732558],"category_scores_gemma":[0.002912099,0.00018620185,0.00014926244,0.00018918386,0.0011589131,0.00012910155,0.00027152494,0.0010000054,0.00027872788],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004337923,0.00030905628,0.8401791,0.00034324362,0.00008306625,0.0024735834,0.00067790167,0.00000455596,0.00030434172,0.0026659966,0.0016318993,0.1508935],"study_design_scores_gemma":[0.008094795,0.00075903756,0.7730352,0.0017354963,0.0003784905,0.002623586,0.00035539654,0.0005730779,0.00014832166,0.0034869504,0.20846134,0.0003482529],"about_ca_topic_score_codex":0.0009733317,"about_ca_topic_score_gemma":0.004543114,"teacher_disagreement_score":0.20682944,"about_ca_system_score_codex":0.00052655634,"about_ca_system_score_gemma":0.0010183796,"threshold_uncertainty_score":0.9998399},"labels":[],"label_agreement":null},{"id":"W2770447500","doi":"10.17925/ohr.2017.13.02.117","title":"Adrenal Oligometastases Secondary to Non-small Cell Lung Cancer—What is the Optimal Treatment Approach?","year":2017,"lang":"en","type":"article","venue":"touchREVIEWS in Oncology & Haematology","topic":"Adrenal and Paraganglionic Tumors","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Lung cancer; Adrenalectomy; Retrospective cohort study; Stage (stratigraphy); Chemotherapy; Radiation therapy; Radical surgery; Cancer; Oncology; Surgery; Internal medicine","score_opus":0.042011681780820424,"score_gpt":0.36247305074150465,"score_spread":0.3204613689606842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770447500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8612082,0.09483023,0.00061604043,0.02109371,0.0011652166,0.003916852,0.000059378737,0.000051727922,0.017058618],"genre_scores_gemma":[0.91294414,0.037959725,0.01277077,0.024300352,0.000991598,0.004301622,0.000113621376,0.0001277652,0.0064904066],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971793,0.00031353583,0.00083912344,0.0007351446,0.00015809695,0.00077476766],"domain_scores_gemma":[0.99748755,0.00031546745,0.0005003825,0.0013066139,0.00008276451,0.00030725516],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00058237807,0.00048566784,0.0020349103,0.00020275089,0.00040286419,0.000056374316,0.0006925374,0.00029040646,0.0011639027],"category_scores_gemma":[0.0000974187,0.00028701758,0.00035177436,0.00018325326,0.0004475901,0.00015930153,0.00029818134,0.0005450775,0.00026487766],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026612412,0.005232636,0.03761725,0.003946063,0.0014784405,0.047970384,0.019551523,0.0005776194,0.00028038485,0.0016589933,0.10973038,0.7692951],"study_design_scores_gemma":[0.014096599,0.0049761045,0.024977874,0.0022373353,0.0027031682,0.04710336,0.002864094,0.0020665408,0.00835858,0.00016257157,0.88903725,0.0014165272],"about_ca_topic_score_codex":0.0005763442,"about_ca_topic_score_gemma":0.00061886624,"teacher_disagreement_score":0.7793069,"about_ca_system_score_codex":0.0003803239,"about_ca_system_score_gemma":0.0009154771,"threshold_uncertainty_score":0.9999582},"labels":[],"label_agreement":null},{"id":"W2800764700","doi":"10.17925/ohr.2018.14.1.21","title":"Pediatric Anaplastic Large Cell Lymphoma—A Review","year":2018,"lang":"en","type":"article","venue":"touchREVIEWS in Oncology & Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; University of Toronto; Hospital for Sick Children","funders":"","keywords":"Anaplastic large-cell lymphoma; Medicine; Lymphoma; Pathology","score_opus":0.022440804423905357,"score_gpt":0.34836774670896703,"score_spread":0.3259269422850617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800764700","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34782684,0.58123744,0.000091480084,0.007384856,0.0015247606,0.0033006682,0.0000198202,0.00016423197,0.058449887],"genre_scores_gemma":[0.5840858,0.38729712,0.002279828,0.024041941,0.0006589083,0.0009026479,0.000074384094,0.00005789791,0.0006014496],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.996579,0.00047504657,0.0012133715,0.00070218794,0.0002030344,0.0008273617],"domain_scores_gemma":[0.9978952,0.0005183603,0.00039439116,0.0007601965,0.00016715216,0.00026472012],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00079509,0.00040296285,0.0023727405,0.00028833435,0.00010339122,0.000005789909,0.00024936555,0.00037027744,0.0019310482],"category_scores_gemma":[0.0004936304,0.0003086635,0.00028663018,0.0007372869,0.00022290816,0.00006663158,0.00016077563,0.00017803987,0.0048396704],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047727124,0.019286754,0.36894867,0.016579498,0.00023015469,0.015578587,0.0006302658,1.537658e-7,0.000029396762,0.0060315235,0.3616814,0.21052633],"study_design_scores_gemma":[0.010709292,0.0026641304,0.020903157,0.0014941887,0.0010978275,0.0046641324,0.00002255789,0.000017956823,0.00019387352,0.00015840685,0.9577428,0.00033166047],"about_ca_topic_score_codex":0.000030267633,"about_ca_topic_score_gemma":0.00024748797,"teacher_disagreement_score":0.5960614,"about_ca_system_score_codex":0.0006984751,"about_ca_system_score_gemma":0.0009848069,"threshold_uncertainty_score":0.9999365},"labels":[],"label_agreement":null},{"id":"W2998181651","doi":"10.17925/ohr.2019.15.2.78","title":"Understanding Survival Disparities in Gastric Cancer","year":2019,"lang":"en","type":"article","venue":"touchREVIEWS in Oncology & Haematology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Cancer; Internal medicine","score_opus":0.1453113158276303,"score_gpt":0.38089018622657717,"score_spread":0.23557887039894687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998181651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89497197,0.018209958,0.00064380845,0.020446451,0.0033194725,0.002700842,0.000005119419,0.00009603075,0.059606347],"genre_scores_gemma":[0.98052335,0.014401289,0.00042710913,0.0024999338,0.000092385395,0.00022373901,0.00001375523,0.000027158081,0.0017912571],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99783355,0.00024313318,0.00073421287,0.00042474022,0.00016435262,0.00060003187],"domain_scores_gemma":[0.9990233,0.00035900078,0.00018270862,0.0003312257,0.000024056852,0.000079696256],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000645827,0.00023171805,0.0016442852,0.0005540341,0.000025263824,0.000007626041,0.00018133178,0.00021721794,0.0015647152],"category_scores_gemma":[0.00011522713,0.00020232613,0.00012585826,0.00069519615,0.0001365699,0.00008763596,0.00012633351,0.000458222,0.00019124872],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013121314,0.00013483026,0.97116584,0.0006107346,0.000042089945,0.00060056994,0.00012247865,0.000023402865,0.000020065836,0.016108882,0.003409173,0.007630715],"study_design_scores_gemma":[0.0138009,0.0010098201,0.7029333,0.0015038203,0.00032695488,0.0009923809,0.0015060006,0.00044447533,0.00002719713,0.0042426414,0.27253923,0.0006732717],"about_ca_topic_score_codex":0.00056063104,"about_ca_topic_score_gemma":0.0046365266,"teacher_disagreement_score":0.26913005,"about_ca_system_score_codex":0.0011968998,"about_ca_system_score_gemma":0.00024599835,"threshold_uncertainty_score":0.999348},"labels":[],"label_agreement":null},{"id":"W3132286526","doi":"10.17925/ohr.2021.16.2.100","title":"<i>MET</i> Exon 14 Skipping Alterations in Non-small Cell Lung Carcinoma—Current Understanding and Therapeutic Advances","year":2021,"lang":"en","type":"article","venue":"touchREVIEWS in Oncology & Haematology","topic":"Liver physiology and pathology","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Current (fluid); Medicine; Lung; Cancer research; Computational biology; Oncology; Internal medicine; Biology; Engineering","score_opus":0.06749003951685331,"score_gpt":0.35215664515223793,"score_spread":0.2846666056353846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3132286526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8314352,0.16072196,0.0019428972,0.0010849168,0.00087302556,0.0008202938,0.0000037221753,0.000025614348,0.0030923835],"genre_scores_gemma":[0.97438395,0.02134365,0.0016599565,0.0021989604,0.0000993847,0.00019389021,0.000041530864,0.00002232973,0.000056364068],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99687517,0.00097168237,0.000831796,0.00067926693,0.00007407687,0.0005679904],"domain_scores_gemma":[0.99845946,0.00076283066,0.00022885451,0.00037679152,0.000062511645,0.00010957862],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005874213,0.0002887587,0.0015427673,0.00030519336,0.000099769866,0.000007426283,0.0001334278,0.0003838173,0.00011939198],"category_scores_gemma":[0.00011303222,0.00027410412,0.00011212131,0.00042576017,0.0003389705,0.00008649075,0.00014935031,0.00082566636,0.000028006529],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055787363,0.002049991,0.80985546,0.005133818,0.00013297974,0.013688517,0.012024131,0.00008440229,0.012564515,0.024487471,0.0006437219,0.11877715],"study_design_scores_gemma":[0.05522046,0.0071849264,0.48210683,0.008733869,0.003244914,0.051768932,0.016381428,0.0047420617,0.012792346,0.06816907,0.28510273,0.0045524286],"about_ca_topic_score_codex":0.00001603703,"about_ca_topic_score_gemma":0.0006829396,"teacher_disagreement_score":0.3277486,"about_ca_system_score_codex":0.0003072174,"about_ca_system_score_gemma":0.00040834962,"threshold_uncertainty_score":0.9999711},"labels":[],"label_agreement":null},{"id":"W4213090277","doi":"10.17925/ohr.2021.17.2.73","title":"Bruton's Tyrosine Kinase Inhibitors for the Treatment of Waldenström's Macroglobulinaemia: A Canadian Perspective","year":2021,"lang":"en","type":"article","venue":"touchREVIEWS in Oncology & Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Janssen Canada; BeiGene","keywords":"Bruton's tyrosine kinase; Perspective (graphical); Waldenstrom macroglobulinemia; Medicine; Tyrosine kinase; Ibrutinib; Internal medicine; Computer science; Leukemia; Receptor; Lymphoma","score_opus":0.04450833492793894,"score_gpt":0.38975086359372274,"score_spread":0.3452425286657838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213090277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.645841,0.27314022,0.00012459263,0.06287692,0.0014900368,0.0068004937,0.00010718931,0.000055671127,0.009563849],"genre_scores_gemma":[0.9460554,0.045022547,0.0029372468,0.002190504,0.00043972343,0.0015922056,0.0000822653,0.00007361652,0.0016065029],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971407,0.0003548045,0.0008505953,0.00061376934,0.00019697522,0.000843136],"domain_scores_gemma":[0.9965352,0.0015348619,0.00020997383,0.00084228074,0.000569727,0.0003079913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047956014,0.00030895235,0.0017570012,0.00025514868,0.00012529013,0.000007762964,0.00023236056,0.00046492665,0.00045527384],"category_scores_gemma":[0.0011919324,0.00021310759,0.0003854926,0.0006284888,0.0006852903,0.000034003882,0.00006820115,0.00029938284,0.00006343897],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0040902174,0.009501362,0.015910828,0.0039401622,0.0029524884,0.13124757,0.020722745,0.0001111205,0.0042288825,0.10420611,0.07099327,0.6320953],"study_design_scores_gemma":[0.024870249,0.0035422745,0.0006379146,0.00045513676,0.0007386765,0.021969138,0.0030343025,0.0009619744,0.017397262,0.0011544373,0.92491245,0.0003261609],"about_ca_topic_score_codex":0.07334517,"about_ca_topic_score_gemma":0.28790197,"teacher_disagreement_score":0.8539192,"about_ca_system_score_codex":0.028624011,"about_ca_system_score_gemma":0.025966184,"threshold_uncertainty_score":0.97955567},"labels":[],"label_agreement":null},{"id":"W4247945137","doi":"10.17925/ohr.2015.11.01.74","title":"Gastrointestinal Stromal Tumors (GIST)—Paving the Way for Modern Oncology—Epidemiology, Diagnosis, Treatment","year":2015,"lang":"en","type":"article","venue":"touchREVIEWS in Oncology & Haematology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Medicine; GiST; Regorafenib; Sunitinib; Imatinib; Oncology; Internal medicine; Stromal tumor; Imatinib mesylate; Surgery; Radiology; Cancer; Stromal cell; Colorectal cancer","score_opus":0.24500849977105757,"score_gpt":0.46073877915552264,"score_spread":0.21573027938446507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247945137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8432998,0.034796976,0.006251243,0.092205696,0.0007630989,0.012898171,0.000099107056,0.0003236858,0.009362231],"genre_scores_gemma":[0.8846531,0.0018375479,0.09670703,0.003389618,0.00056199974,0.011748514,0.0002405677,0.00012108297,0.0007405641],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99327916,0.0019625407,0.001745675,0.0010099942,0.00024665648,0.0017560011],"domain_scores_gemma":[0.99114877,0.006103266,0.0006489062,0.0009187838,0.0003469702,0.0008332741],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0035086705,0.00065447635,0.0031996998,0.00029243564,0.00020624077,0.000012347712,0.0004915113,0.00021038002,0.00012179163],"category_scores_gemma":[0.008712422,0.00040345106,0.00053098734,0.00031822483,0.0011176418,0.00008744204,0.00022578536,0.0008091497,0.0002250379],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003537851,0.0054103783,0.7554237,0.0004194727,0.00031031086,0.017046865,0.0005962192,0.00011973165,0.00014792934,0.006379976,0.025033016,0.18557455],"study_design_scores_gemma":[0.031240895,0.09772651,0.047044422,0.0024844015,0.0013977581,0.28310648,0.0018976642,0.0051308987,0.00048601333,0.017660668,0.5108062,0.0010181175],"about_ca_topic_score_codex":0.00047734953,"about_ca_topic_score_gemma":0.0013621075,"teacher_disagreement_score":0.70837927,"about_ca_system_score_codex":0.0027706567,"about_ca_system_score_gemma":0.0019413785,"threshold_uncertainty_score":0.99984175},"labels":[],"label_agreement":null}]}